GYNECOLOGIC CANCERS

Noah D. Kauff, MD, FACOG, gynecologist and geneticist, director, Ovarian Cancer Screening and Prevention, Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses unanswered questions regarding the treatment of patients with uterine cancer.

A more than 25-month improvement in overall survival was seen with lyso-thermosensitive liposomal doxorubicin (LTLD; ThermoDox) combined with optimized (?45 minutes dwell time) radiofrequency ablation in patients with hepatocellular carcinoma.

Frederic Amant, MD, PhD, assistant professor, gynecologic oncologist, head of the scientific section of gynecologic oncology at Katholieke Universiteit in Leuven, Belgium, the impacts of chemotherapy on pregnant woman and their babies.

Tom Herzog, MD, clinical director, University of Cincinnati Cancer Institute, explains the impact ADXS11-001 may have on patients with recurrent metastatic cervical cancer who currently have limited effective treatment options.

Significantly improved emesis control was seen when fosaprepitant was added to an antiemetic regimen compared with standard care, in women receiving radiotherapy and cisplatin for cervical cancer.

Treatment with nivolumab demonstrated clinical efficacy and safety in patients with platinum-resistant, recurrent, or advanced ovarian cancer.

Patients with advanced lung and gastrointestinal neuroendocrine tumors had a 52% reduction in risk of progression or death with everolimus compared with placebo.

A novel immunotherapy, EGEN-001, combined with pegylated liposomal doxorubicin (PLD) has demonstrated clinical benefit in recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer patients.

The fully human PD-L1 IgG1 antibody, avelumab, demonstrated clinical activity in patients who have previously treated, recurrent/refractory (R/R) ovarian cancer.

Results of the CHORUS trial confirm the noninferiority of primary chemotherapy followed by surgery versus primary surgery and then chemotherapy, and show that performing chemotherapy first is associated with less morbidity and mortality in patients with newly diagnosed, advanced ovarian cancer.

Jeffrey N. Weitzel, MD, director, Clinical Cancer Genetics, director, Cancer Screening & Prevention Program Network, professor, City of Hope, discusses the impact of gene mutations on treatment.

A novel basket trial has reported results on the treatment of vemurafenib in variety of nonmelanoma cancers with BRAF V600 mutation.

Patients with epithelial ovarian cancer who took non-selective beta blockers (NSBBs) during chemotherapy had significantly improved overall survival (OS) than those who did not.

Young black women have a higher prevalence of BRCA mutations compared with that previously reported among non-Hispanic white women.

Recent therapeutic advances have almost doubled the survival of patients with metastatic pancreatic cancer, and the availability of highly active chemotherapy regimens is making personalized medicine a reality.

Eric Van Cutsem, MD, PhD, discusses regorafenib for the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC).

Sonidegib (Odomzo) was approved by the EC for the treatment of patients who have locally advanced basal cell carcinoma (laBCC) and are not amenable to curative surgery or radiation therapy.

Nooshin Hashemi Sadraei, MD, assistant professor of medicine, Department of Internal Medicine, University of Cincinnati, discusses the challenges of treating HPV-induced tumors.

Evidence is mounting for multigene panel testing in women with suspected familial breast and/or ovarian cancer.

Robert L. Coleman, MD, professor, Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, vice chair, Clinical Research, The University of Texas MD Anderson Cancer Center, discusses the toxicities associated with rucaparib in patients with ovarian cancer.

Andrew Hendifar, MD, MPH, assistant professor of medicine, Cedars Sinai Medical Center and the David Geffen School of Medicine, discusses PEGPH20 with nab-paclitaxel/gemcitabine in pancreatic cancer.

Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell, discusses the results of the METGastric study.

Philip Philip MD, PhD, professor of oncology at Karmanos Cancer Center, Wayne State University School of Medicine, discusses current research on pancreatic cancer, as well as funding, awareness, and treatment options.

Rosemary Cress, MPH, PhD, and colleagues sought to identify long-term survival of patients with epithelial ovarian cancer, as well as the epidemiological characteristics associated with such survival.

Combination therapy with birinapant and carboplatin may be more effective than either therapy alone for treatment of high-grade serous ovarian cancers (HGSCs) with high levels of cellular inhibitor of apoptosis protein (cIAP) in their CA125-negative cells.